Abstract: The present disclosure provides a medical device (100) for inducing cell death in cancer cells. The device comprises a signal generator (102) arranged to generate a pulsed electrical signal, and a transmitter (116) arranged to receive the pulsed electrical signal and generate, in response to the electrical signal, an electric field in a treatment volume. The device (100) is arranged such that the pulsed electrical signal received by the transmitter (116) has a pulse width of 0.1 microsecond to 1 millisecond, and a signal frequency of 10 Megahertz to 20 Gigahertz. The present disclosure also provides a method of inducing cell death. The method comprising a step of generating, using a transmitter (116), a pulsed time varying electric field in a treatment volume comprising a volume of cells to be treated. The electric field has a pulse width of 0.1 microsecond to 1 millisecond, and a signal frequency of 10 Megahertz to 20 Gigahertz.

Abstract: The invention relates to at least one molecular target for healing or treating wounds and, in particular chronic, human wounds. The molecular target is nWASP or a protein at least 75% homologous therewith and which retains the same activity as nWASP protein, such as WASP. Further, the invention concerns a novel therapeutic for treating said wounds and a novel gene therapy approach, involving said molecular target, for treating said wounds.

Abstract: A method and kit are provided for identifying non-healing or healing chronic mammalian wound tissue or for determining the prognosis of chronic mammalian wound tissue based upon the identification of at least one key set of molecular markers or genes whose expression pattern is indicative of a given wound type and so representative of a given prognosis.

Abstract: The invention relates to at least one molecular target for healing or treating wounds and, in particular chronic, human wounds. The molecular target is nWASP or a protein 50% homolgous therewith and which retains the same activity as nWASP protein, such as WASP. Further, the invention concerns a novel therapeutic for treating said wounds and a novel gene therapy approach, involving said molecular target, for treating said wounds.

Abstract: A method and kit are provided for identifying non-healing or healing chronic mammalian wound tissue or for determining the prognosis of chronic mammalian wound tissue based upon the identification of at least one key set of molecular markers or genes whose expression pattern is indicative of a given wound type and so representative of a given prognosis.

Abstract: The present invention relates to a method and kit, including parts thereof, for the prognosis of breast cancer. In particular, the method involves identifying a gene expression pattern, or molecular signature, that indicates the likelihood of survival of a patient with breast cancer, and/or likelihood of recurrence of the disease in a patient being treated, or having been treated, for breast cancer, and the likelihood of a patient having a metastatic form of cancer. Six molecular signatures, comprising twelve groups/sets of molecular markers have been identified, which have relevance in determining the prognosis of a given breast cancer. Each molecular signature comprises a plurality of genetic markers whose expression, either high or low in respect of normal tissue, is indicative of a given outcome, such as survival or recurrence.

Abstract: The invention relates to a novel therapeutic composition for treating cancer, and particularly prostrate and breast cancer, the composition comprises mixture of two hepatocyte growth factor activator inhibitors HAI-1 and HAI-2.